Keymed Biosciences Inc. (2162.HK)
HKD 33.0
(-1.93%)
HKD 33.0
(-1.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -432.32 Million CNY | 10.33% |
| 2022 | -482.1 Million CNY | 67.46% |
| 2021 | -1.48 Billion CNY | -1017.63% |
| 2020 | -132.54 Million CNY | 62.79% |
| 2019 | -356.16 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 9.63 Million CNY | 330.05% |
| 2024 Q1 | 9.63 Million CNY | 102.23% |
| 2023 Q3 | -392.53 Million CNY | 49.92% |
| 2023 FY | -432.32 Million CNY | 10.33% |
| 2023 Q2 | -783.79 Million CNY | 2.25% |
| 2023 Q4 | -432.32 Million CNY | -10.14% |
| 2023 Q1 | -801.82 Million CNY | -66.32% |
| 2022 Q2 | -1.02 Billion CNY | 1.2% |
| 2022 Q1 | -1.03 Billion CNY | 29.92% |
| 2022 FY | -482.1 Million CNY | 67.46% |
| 2022 Q4 | -482.1 Million CNY | 2.2% |
| 2022 Q3 | -492.95 Million CNY | 51.94% |
| 2021 FY | -1.48 Billion CNY | -1017.63% |
| 2021 Q4 | -1.48 Billion CNY | 0.79% |
| 2021 Q3 | -1.49 Billion CNY | -85.59% |
| 2021 Q2 | -804.5 Million CNY | -116.87% |
| 2021 Q1 | 4.77 Billion CNY | 3698.89% |
| 2020 FY | -132.54 Million CNY | 62.79% |
| 2020 Q4 | -132.54 Million CNY | -110.61% |
| 2020 Q3 | 1.24 Billion CNY | 0.0% |
| 2020 Q1 | 499.01 Million CNY | 0.0% |
| 2019 FY | -356.16 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -466.094% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 108.208% |